Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Rockwell Medical (RMTI) over the last 3 years, with Mar 2011 value amounting to $34.9 million.

  • Rockwell Medical's Cash & Equivalents rose 10.31% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 10.31%. This contributed to the annual value of $15.7 million for FY2024, which is 74.35% up from last year.
  • According to the latest figures from Q3 2025, Rockwell Medical's Cash & Equivalents is $13.6 million, which was up 9.04% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, Rockwell Medical's Cash & Equivalents ranged from a high of $35.7 million in Q1 2021 and a low of $6.6 million during Q1 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $11.4 million (2025), whereas its average is $11.0 million.
  • Its Revenue - Interest and Investment Income has fluctuated over the past 5 years, first surged by 285.15% in 2010, then dropped by 1.66% in 2011.
  • Over the past 3 years, Rockwell Medical's Revenue - Interest and Investment Income (MRQ) stood at $34.9 million in 2009, then rose by 5.99% to $37.0 million in 2010, then dropped by 5.62% to $34.9 million in 2011.
  • Its Cash & Equivalents was $13.6 million in Q3 2025, compared to $12.5 million in Q2 2025 and $11.4 million in Q1 2025.